FICT vs ELISA: Single Test Against Batch

Quick Answer — ELISA and point-of-care fluorescence are both immunoassays; the difference is where the work happens and when the answer arrives. ELISA buys precision and cost per test at volume, at the price of hours to days of latency. A point-of-care cartridge buys same-visit latency, at a higher cost per test and with performance dependent on clinic handling. The decision is about the decision the result will serve.

The comparison

Dimension	ELISA (laboratory)	FICT (point-of-care)
Throughput model	Batch — plates of samples	Single sample, on demand
Turnaround	Hours to next day	Minutes
Cost per test at volume	Lower	Higher
Cost per test at low volume	High (controls, plates, labour)	Comparable or lower
Precision	High, with established controls	Good, dependent on handling
Operator skill	Trained technician	Clinic staff
Result comparability	Method-specific	Method-specific
Best use	Screening, research endpoints, panels	Same-day clinical decisions

Where ELISA still wins

1. Batch screening. Population studies, breeding programmes, research cohorts — economies of scale are real.
2. Research endpoints requiring traceable values and documented plate-level QC.
3. Panels where many analytes are measured from one sample.
4. Low urgency: a result that will be reviewed tomorrow does not need to be produced today.

Where point-of-care wins

1. Acute presentations where treatment, isolation or discharge depends on the answer.
2. Single samples where the fixed costs of a plate cannot be amortised.
3. Clients who will not return for a follow-up visit to receive a result.
4. Outbreak settings where same-day isolation decisions prevent transmission.

The precision question, asked properly

The useful comparison is not “POCT versus ELISA” but the CV of the specific assay at the relevant concentration. A well-run ELISA can have CVs in the low single digits; a poorly handled cartridge can be worse than the insert states. Conversely, a well-run cartridge can outperform an ELISA that is batched irregularly with infrequent controls.

Data pending. This section reports measured values from internal validation studies. They are published once the supporting study is complete; the current report is available from technical support on request.

The bias question

Different immunoassays produce different absolute values for the same analyte. A clinic switching from a laboratory ELISA to a point-of-care assay will see a systematic shift, and any reference interval or decision limit carried across will be wrong.

Data pending. This section reports measured values from internal validation studies. They are published once the supporting study is complete; the current report is available from technical support on request.

The Author’s Take

Position. The honest framing is that ELISA remains the better instrument for batch work and POCT is the better instrument for decisions — and a vendor that says so converts more informed buyers than one that claims outright superiority.

Reasoning. Laboratory-trained buyers know that batch assays are efficient and precise; a claim of general superiority invites scepticism and a test drive that ends in a comparison table the vendor did not control. The narrower claim — “we are not trying to replace your plate reader, we are trying to replace the two-day wait on the cases that cannot wait” — is credible, fits the buyer’s existing workflow, and positions the platform as an addition rather than a threat. That is a far easier procurement conversation, especially where the laboratory director is protective of existing validated methods.

Disclosure. This page compares method categories, not specific products. Figures marked indicate where platform-specific comparison data must be inserted.

Sources

1. Reference to be added.
2. Reference to be added.
3. CLSI EP05 / EP09 — precision and method comparison.